Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Immortal Style: Closet Staples for Each Age - 2Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- 3The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- 4Compassion and Association: Building Significant Connections
- 5Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- Remote Headphones: Improve Your Sound Insight
- Pfizer says patient dies after receiving hemophilia drug in trial
- Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- 21 Incredibly Interesting Contemplations To Observe Consistently
- Support Your Body: A Manual for Smart dieting and Sustenance
- 5 Bike Brands for Ordinary Use
- Recalled "super greens" supplement linked to dozens of salmonella cases, CDC says
- Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- NASA Perseverance rover sees megaripples on Mars | Space photo of the day for Jan. 7, 2026.
